VERA · Vera Therapeutics, Inc. · Documents

Jun 12

Current report 8-K Events of Jun 7

Director or officer change, or executive pay

May 17

Current report 8-K Events of May 15

Shareholder vote results

May 10

Quarterly report 10-Q FY2024 Q1, ended Mar 31

Quarterly report for FY2024 Q1

Net loss $28.38M Diluted EPS -$0.56

May 9

Current report 8-K

Financial results

May 3

Proxy statement DEFA14A

Proxy statement

Apr 4

Annual report to holders ARS

Annual report to holders

Apr 3

Proxy statement DEF 14A Meeting May 15, 2024

Proxy statement

Apr 3

Proxy statement DEFA14A

Proxy statement

Mar 27

Annual report 10-K FY2023, ended Dec 31

Annual report for FY2023

Net loss $95.99M Diluted EPS -$2.25

Mar 20

Current report 8-K

Financial results

Jan 30

Current report 8-K Events of Jan 29

Other events

Jan 29

Current report 8-K

Financial results, Other events

Jan 25

Current report 8-K

Regulation FD disclosure, Other events

Jan 8

Current report 8-K

Regulation FD disclosure

Jan 8

Current report 8-K Events of Jan 3

Director or officer change, or executive pay, Regulation FD disclosure

Dec 26

Current report 8-K Events of Dec 22

New debt or off-balance-sheet obligation

Nov 9

Current report 8-K

Financial results

Nov 9

Quarterly report 10-Q FY2023 Q3, ended Sep 30

Quarterly report for FY2023 Q3

Net loss $20.1M Diluted EPS -$0.45

Aug 10

Current report 8-K

Financial results

Aug 10

Quarterly report 10-Q FY2023 Q2, ended Jun 30

Quarterly report for FY2023 Q2

Net loss $20.16M Diluted EPS -$0.46

Jun 20

Current report 8-K Events of Jun 17

Regulation FD disclosure, Other events

May 17

Current report 8-K Events of May 10

Shareholder vote results

May 11

Current report 8-K

Financial results

May 11

Quarterly report 10-Q FY2023 Q1, ended Mar 31

Quarterly report for FY2023 Q1

Net loss $30.07M Diluted EPS -$0.80

Mar 30

Proxy statement DEF 14A Meeting May 10, 2023

Proxy statement

Mar 30

Annual report to holders ARS

Annual report to holders

Mar 30

Proxy statement DEFA14A

Proxy statement

Mar 28

Current report 8-K

Financial results

Mar 28

Annual report 10-K FY2022, ended Dec 31

Annual report for FY2022

Net loss $89.06M Diluted EPS -$3.35

Mar 10

Current report 8-K

Other events

Feb 2

Current report 8-K Events of Feb 1

Other events

Feb 1

Current report 8-K

Financial results

Jan 30

Current report 8-K

Regulation FD disclosure, Other events

Jan 3

Current report 8-K

Regulation FD disclosure, Other events

Nov 9

Current report 8-K

Financial results

Nov 9

Quarterly report 10-Q FY2022 Q3, ended Sep 30

Quarterly report for FY2022 Q3

Net loss $24.68M Diluted EPS -$0.91

Sep 9

Current report 8-K

Entered into a material agreement, Other events

Aug 10

Current report 8-K

Financial results

Aug 10

Quarterly report 10-Q FY2022 Q2, ended Jun 30

Quarterly report for FY2022 Q2

Net loss $14.85M Diluted EPS -$0.55

Jun 3

Registration statement S-3

Registration statement

May 26

Current report 8-K Events of May 24

Shareholder vote results

May 16

Current report 8-K

Financial results

May 16

Quarterly report 10-Q FY2022 Q1, ended Mar 31

Quarterly report for FY2022 Q1

Net loss $17.09M

Apr 14

Proxy statement DEF 14A Meeting May 24, 2022

Proxy statement

Apr 14

Proxy statement DEFA14A

Proxy statement

Apr 12

Current report 8-K Events of Apr 7

Director or officer change, or executive pay

Mar 28

Annual report 10-K FY2021, ended Dec 31

Annual report for FY2021

Net loss $32.61M

Mar 24

Current report 8-K

Financial results

Feb 7

Registration statement S-1

Registration statement

Dec 17

Current report 8-K

Entered into a material agreement, New debt or off-balance-sheet obligation, Other events